A 59-Year-Old Man With Relapsed Follicular Lymphoma
A 59-Year-Old Man With Relapsed Follicular Lymphoma
Case: A 59-Year-Old Man With Symptomatic Follicular Lymphoma
A 59-year-old man presented to his physician with a 10-lb weight loss and chronic night sweats for the past couple of months. He complained of intermittent fatigue but is able to maintain his current exercise regimen.
H & P
- PE: enlarged bilateral axillary lymph nodes; enlarged spleen, palpable
- CBC: WBC, 12 X 104/L; platelets,103 X 109/L; Hgb, 9.2 g/dL
- LDH: 400 U/L
Biopsy
- Excisional biopsy showed grade 2 follicular lymphoma; CD20+, CD10+
- Bone marrow biopsy; 60% involved
Imaging
- PET/CT showed widespread lymphadenopathy and a large splenic mass measuring 10 cm
- Diagnosis: Stage IV follicular lymphoma
Teatment
- Started on R-CHOP; tolerated induction well
- Post-therapy PET showed partial remission
- Followed by Rituximab maintenance until evidence of disease progression
Follow-up
- Core needle biopsy; performed confirmed persistent follicular lymphoma; no transformation
- PET at 12 months showed increased size of splenic mass
- ECOG, 0
- Patient started on obinutuzumab + bendamustine
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
February 27th 2024If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.
Read More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
December 11th 2023Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Read More
